Protocol Ledger

NCT04492475 · Phase III · COMPLETED

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Interventional Phase III clinical trial protocol NCT04492475 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-05 Enrollment: 969 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04492475
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)969 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04492475
Protocol FieldVerified Registry Value
NCT IdentifierNCT04492475
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment969 participants (ACTUAL)
Registered Start Date2020-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI